Microalbuminuria in hypertension

Current Hypertension Reports

Volumn 5, Issue 3, 2003, Pages 208-214

  Palatini, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FELODIPINE; LISINOPRIL; RAMIPRIL; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR RISK; DEMOGRAPHY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; MICROALBUMINURIA; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URINARY EXCRETION; ALBUMINURIA; CARDIOVASCULAR DISEASE; HEMODYNAMICS; RISK ASSESSMENT; RISK FACTOR; URINE; VASCULAR DISEASE;

ALBUMINURIA; CARDIOVASCULAR DISEASES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS; VASCULAR DISEASES;

EID: 0141688141     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0022-0     Document Type: Review

References (50)

1. Redon J, Williams B: Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002, 353-355.
2. Rosa TT, Palatini P: Clinical value of microalbuminuria in hypertension. J Hypertens 2000, 18:645-654.
3. Damsgaard EM, Froland A, Jorgensen OD, et al.: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990, 300:297-300.
4. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al.: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999, 19:1992-1997.
5. Roest M, Banga JD, Janssen WM, et al.: Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001, 103:3057-3061.
6. Gerstein HC, Mann JF, Yi Q, et al.: Hope Study Investigators. Albuminuria and risk of cadiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-426.
7. American Diabetes Association and the National Kidney Foundation: Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994, 17:1357-1361.
8. Terpstra WF, May JF, Smith AJ, et al.: Microalbuminuria is related to marked end organ damage in previouly untreated, elderly hypertensive patients. Blood Press 2002, 11:84-90.
9. Hillege HL, Janssen WM, Bak AA, et al.: for the Prevend Study Group: Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001, 249:519-526.
10. Dell'Omo G, Penno G, Giorgi D, et al .: Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002, 40:1-8.
11. Pedrinelli R, Dell'Omo G, Di Bello V, et al.: Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002, 16:79-89.
12. Martinez MA, Moreno A, Aguirre de Carcer A, et al., MAPA - Madrid Working Group: Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study. J Hypertens 2001, 19:319-326.
13. Jones CA, Francis ME, Eberhardt MS, et al.: Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002, 39:445-459.
14. Wachtell K, Olsen MH, Dahlof B, et al.: Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Life study. J Hypertens 2002, 20:405-412.
15. Palatini P, Graniero GR, Mormino P, et al.: Prevelance and clinical correlates of microalbuminuria in stage I hypertension. Results from the Hypertension and Ambulatory Recording Venetia study (Harvest Study). Am J Hypertens 1996, 9:334-341.
16. Cirillo M, Senigalliesi L, Laurenzi M, et al.: Microalbuminuria in nondiabetic adults. Arch Intern Med 1998, 158:1933-1939.
17. Pontremoli R, Nicolella C, Viazzi F, et al.: Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998, 11:430-438.
18. de la Sierra A, Bragulat E, Sierra C, et al.: Microalbuminuria in essential hypertension: clinical and biochemical profile. Br J Biomed Sci 2000, 57:287-291.
19. Halimi JM, Forhan A, Balkau B, et al., D.E.S.I.R. Study Group: Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001, 8:139-146.
20. Toft I, Bonaa KH, Eikrem J, et al.: Microalbuminuria in hypertension is not a determinant of insulin resistance. Kidney Int 2002, 61:1445-1452.
21. Mennen LI, Balkau B, Royer B, et al.: Microalbuminuria and markers of the atherosclerotic process: the Desir study. Atherosclerosis 2001, 154:163-1619.
22. Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002, 7:35-43.
23. Leoncini G, Sacchi G, Viazzi F, et al.: Microalbuminuria identifies overall cardiovascular risk in essential hypertensions: an artificial neural network-based approach. J Hypertens 2002, 20:1315-1321.
24. Diercks GF, van Boven AJ, Hillege HL, et al.: Microalbuminuria is independently associated with ischaemic eletrocardiographic abnormalities in a large non-diabetic population. The PREVENT (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J 2000, 21:1922-1927.
25. Turaj W, Slowik A, Wyrwicz-Petkow U, et al.: The prognostic sgnificance of microalbuminuria in non-diabetic acute stroke patients. Med Sci Monit 2001, 7:989-994.
26. Berton G, Cordiano R, Mbaso S, et al.: Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial infraction. J Hypertens 1998, 16:525-530.
27. Redon J. Baldo E, Lurbe E, et al.: Microalbuminuria, left ventricular mass and ambulatory blood presure monitoring. Kidney Int 1996, 49:S81-S84.
28. Pontremoli R, Ravera M, Bezante GP, et al.: Left venticular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999, 17:993-1000.
29. Leoncini G, Sacchi G, Ravera M, et al.: Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002, 16:399-404.
30. Wachtell K, Palmieri V, Olsen MH, et al.: Urine albumin/creatinine ratio and echocardiographic left venticular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the life study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002, 143:319-326.
31. Gerstein HC, Mann JF, Pogue J, et al.: Prevalance and determinants of microalbuminurai in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The Hope study Inverstigators. Diabetes Care 2000, 23, (Suppl 2):B35-B39.
32. Ebihara I, Nakamura T, Shimada N, et al.: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 2000, 32:669-671.
33. Pedrinelli R, Penno G, Dell'Omo G, et al.: Microalbuminuria and transcapillary albumin leakage in essential hypertension Hypertension 1999, 34:491-495.
34. Agewall S, Wikstrand J. Ljungman S, et al.: Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factors Intervention Study Group. Am J Cardial 1997, 80:164-169.
35. Bulpitt CJ, Beevers DG, Butler A, et al.: The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J Hypertens 1986, 4:93-99.
36. Bigazzi R, Bianchi S, Baldari D, et al.: Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998, 16:1325-1333.
37. Jager A, Kostense PJ, Ruhe HG, et al.: Microalbuminuria and peripheral arterial disease are independently predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999, 19:617-624.
38. Jensen JS, Feldt-Rasmussen B, Strandgard S, et al.: Arterial hypertension, microalbuminuria, and ischemic heart disease. Hypertension 2000, 35:898-903.
39. Redon J, Rovira E, Miralles A, et al.: Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002, 39:794-798.
40. Redon J: Renal protection with antihypertensive drugs: insights from the microalbuminuria studies. J Hypertens 1998, 16:2091-2100.
41. Monster TB, Janssen WM, de Jong PE, et al.: PREVEND Study Group: The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 2002, 53:31-36.
42. Erley CM, Haefele U, Heyne N, et al.: Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993, 21:810-815.
43. Agrawal B, Wolf K, Berger A, et al.: Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996, 10:551-555.
44. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000, 321:1440-1444.
45. Berger ED, Bader BD, Ebert C, et al.: Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002, 20:739-743.
46. Parving HH, Hovind P: Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin IIreceptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 2002, 4:387-393.
47. Andersen NH, Mogensen CE: Angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria. Curr Hypertens Rep 2002, 4:394-402.
48. Remuzzi A, Perico N, Sangalli F, et al.: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999, 276:F457-F466.
49. Bakris GL: Microalbuminuria: what is it? Why is it important? What should be done about it? J Clin Hypertens 2001, 3:99-102.
50. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999, 33:1004-1009.